FDA – Assessing Genetic Heterogeneity in the Context of Genome Editing Off-Targets in Gene Therapy Products (Cell and Gene Therapy Catapult – Regulatory Round-up – November 2022)
FDA is holding public workshop on 16th December 2022 to discuss the impact of individual genetic heterogeneity on genome editing, and best practices for validating off-target editing events in the context of human genetic heterogeneity. The...





